{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:23:52Z","timestamp":1792232632339,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jns.2024.123157","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:58:07Z","timestamp":1722254287000},"page":"123157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Factor XI inhibitors \u2013 Rising stars in anti-thrombotic therapy?"],"prefix":"10.1016","volume":"464","author":[{"given":"Christian H.","family":"Nolte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123157_bb0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostasiologie"},{"key":"10.1016\/j.jns.2024.123157_bb0010","article-title":"Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis","volume":"1-12","author":"Deitelzweig","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jns.2024.123157_bb0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41569-023-00872-4","article-title":"Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale","volume":"20","author":"Ten Cate","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jns.2024.123157_bb0020","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georg","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2024.123157_bb0025","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburg","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jns.2024.123157_bb0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868 a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jns.2024.123157_bb0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123157_bb0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthoplasty; the FOXTROT randomized clinical trial","volume":"323","author":"Jl","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2024.123157_bb0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor Xia inhibitor asundexian compared with apixaban in patients with atrial fibrillations (PACIFIC AF): a mulcicentre randomized double blind double dummy dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123157_bb0065","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter phase 2 randomized placebo-controlled, double-blind, parallel group, dose-finding trial of the oral factor XIa inhibitor Asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123157_bb0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor xi inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-stroke): an international randomized, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123157_bb0075","first-page":"392","article-title":"PACIFIC-stroke steering committee and investigators effect of the factor xia inhibitor asundexian according to baseline infarct pattern and on MRI covert infarct outcomes stroke","volume":"55","author":"Smith","year":"2024"},{"key":"10.1016\/j.jns.2024.123157_bb0080","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123157_bb0090","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"AXIOMATIC-TKR investigators. Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123157_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123157_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: a review","volume":"296","author":"Croke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2024.123157_bb0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Faktor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:56:36Z","timestamp":1724486196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"alternative-id":["S0022510X24002922"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123157","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI inhibitors \u2013 Rising stars in anti-thrombotic therapy?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123157"}}